Organogenesis Trial Failure Sinks Stock Price
ReNu's second trial for knee pain (OA) missed its main goal, but still showed numerical improvement and function benefits. Organogenesis, confident in the data from all three large studies (1,300+ patients), will ask the FDA to review combined results for approval.
Already have an account? Sign in.